Drug-development software and consulting using biosimulation to design and speed up pharma clinical trials.
Drug-development software and consulting using biosimulation to design and speed up pharma clinical trials.
Sells annual software licences for its modelling tools and fee-for-service projects in which its scientists run the models and write regulatory submissions for drug developers; services are the larger of its two segments. Project starts depend partly on how well funded drug developers are.
Moat: narrow (installed base, switching costs, regulatory licence). Simcyp is embedded in regulatory submissions; switching simulation platforms mid-program is costly.
Headquarters: Princeton, New Jersey, US · Founded: 2008 · Employees: 1,576
Size Certara (CERT) is a United States Information Technology company (Packaged Software) with a market value of $1.71B, the 1875th largest of 3,085 United States companies the cockpit tracks. Shares closed at $11.18 on 18 Nov 2026.
Performance Over six months the shares gained 139.4%, against -14.5% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue fell 4.0% over the last twelve months (peer median +11.8%); the operating margin is 4.4% (peer median 4.6%).
Valuation It trades at 27.9× forward earnings against a peer median of 26.9× (10th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 40% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +29 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 9.4 points below its cost of capital (10.7% WACC).
Backlog Backlog (remaining performance obligations) was $128M at 30 Sep 2026, down 13% on a year earlier — 0.3 years of trailing revenue. Backlog detail →
Short interest Short interest is 16.7% of the free float (30 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $399M | $419M | $385M | $354M | $336M |
| Revenue growth | — | +9% | +9% | +6% | — |
| Gross profit | $199M | $201M | $177M | $168M | $160M |
| EBITDA | $88.5M | $101M | $86.8M | $70.1M | $88.4M |
| Net income | -$7.60M | -$1.59M | -$12.1M | -$55.4M | $14.7M |
| Free cash flow | $78.2M | $94.6M | $78.8M | $81.0M | $91.1M |
| Capital expenditure | $29.7M | $26.6M | $21.0M | $15.3M | $12.5M |
| Total debt | $301M | $305M | $312M | $298M | $308M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Certara CERT | $1.71B | +139% | -4% | 4% | 27.9× | 40.1% |
| Simulations Plus SLP | n/a | +48% | n/a | n/a | n/a | n/a |
| ICON ICLR | $14.6B | +70% | +1% | 10% | 17.3× | 15.9% |
| Iqvia IQV | $42.5B | +50% | +9% | 14% | 18.7× | 16.8% |
| Veeva Systems VEEV | $44.9B | +68% | +16% | 30% | 28.7× | 23.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CERT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +14.3% | -3.7% | 2nd highest of 21 |
| 6-month return | +139.4% | -14.5% | highest of 21 |
| Distance from 52-week high | -11.3% | -40.7% | 4th highest of 21 |
| Revenue growth (TTM) | -4.0% | +11.8% | 4th lowest of 21 |
| Operating margin | 4.4% | 4.6% | 11th highest of 21 |
| Forward P/E | 27.9× | 26.9× | 10th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 40.1% | 14.8% | 3rd most demanding of 16 |
| Growth delivered (Del g) | +11.5% | +6.8% | 6th highest of 15 |
| Hurdle (Req g minus delivered) | +28.7 pp | +15.3 pp | 3rd most demanding of 15 |
| ROIC minus cost of capital | -9.4 pp | -5.2 pp | 7th lowest of 18 |
| EV / EBITDA | 20.2× | 7.1× | 2nd most expensive of 9 |
| Net debt / EBITDA | 1.0× | -0.9× | 2nd most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Certara CERT | United States | $1.71B | +139% | -4% | 4% | 27.9× | 40.1% | +11.5% |
| Nazara Technologies NAZARA.NS | India | $1.71B | +41% | -2% | 3% | 139.2× | n/a | n/a |
| Kfin Technologies KFINTECH.NS | India | $1.73B | +13% | +27% | 32% | 41.4× | n/a | n/a |
| China TransInfo Technology 002373.SZ | China | $1.73B | -14% | +16% | 1% | 36.2× | 20.0% | -2.7% |
| Tianyu Digital Technology 002354.SZ | China | $1.67B | +11% | +8% | -2% | 113.0× | 22.2% | +15.8% |
| Wealthfront WLTH | United States | $1.67B | -8% | +18% | -41% | 26.9× | -3.7% | n/a |
| Zhejiang Digital Culture Technology 600633.SS | China | $1.75B | -25% | +14% | 10% | 17.6× | 12.3% | -2.8% |
| Adeia ADEA | United States | $1.65B | -43% | +22% | 44% | 11.3× | 2.5% | -13.0% |
| eToro ETOR | United States | $1.65B | -49% | +1% | 28% | 9.8× | n/a | n/a |
| Business-Intelligence of Oriental Nations 300166.SZ | China | $1.76B | -41% | +7% | -5% | 88.1× | n/a | n/a |
| Aisino 600271.SS | China | $1.77B | -20% | -12% | -24% | 23.6× | n/a | n/a |
| Zhejiang Jinke Tom Culture Industry 300459.SZ | China | $1.78B | -15% | -10% | -108% | n/a | 40.7% | -12.5% |
| Donnelley Financial Solutions DFIN | United States | $1.62B | +70% | +5% | 20% | 12.2× | -4.5% | -3.0% |
| Hacksaw HACK.ST | Sweden | $1.62B | -35% | +21% | 82% | 8.0× | -10.3% | +85.9% |
| Hydsoft Technology 301316.SZ | China | $1.81B | -46% | +19% | 3% | 153.8× | 45.5% | +26.7% |
| Sinosoft 603927.SS | China | $1.61B | -20% | -24% | 2% | 40.3× | 20.6% | +0.9% |
| MIXI 2121.T | Japan | $1.60B | +51% | +30% | 14% | 9.9× | -18.0% | +7.5% |
| ArcSoft 688088.SS | China | $1.60B | -35% | +10% | 12% | 44.5× | 37.5% | +6.2% |
| Five9 FIVN | United States | $1.84B | +9% | +10% | 6% | 6.8× | 14.8% | +21.4% |
| iReader Technology 603533.SS | China | $1.58B | +1% | +14% | -2% | 72.8× | 31.8% | +9.5% |
| iFAST AIY.SI | Singapore | $1.85B | -10% | +35% | 24% | 18.3× | -11.9% | +24.8% |
Certara reported $128M of remaining performance obligations at 30 Sep 2026, down 13% from a year earlier and down 15% from the previous quarter. That is 0.3 years of trailing revenue already under contract. Book-to-bill last quarter: 0.76.